# PharmAgents2: Towards Autonomous End-to-End Drug Discovery

DevFeed: [PharmAgents2: Towards Autonomous End-to-End Drug Discovery](<https://devfeed.tech/articles/pharmagents2-towards-autonomous-end-to-end-drug-discovery-120228.md>)

Original publisher: [Read original article](<https://arxiv.org/abs/2611.07653>)

Author: Haichuan Tan, Bowen Gao, Tao Huang, Jiaxin Tan, Xin Hong, Baoguo Yao, Yifei Wang, Zhichao Deng, Hanji Du, Dapeng Jiang, Yiheng Li, Weiwei Ma, Xin Ma, Yuqi Shi, Zixiang Wang, Kelin Wu, Tianxiang Wu, We

Published: 2026-11-06T05:00:00Z

Content type: article

Language: en

Sources: [arXiv: Artificial Intelligence](<https://devfeed.tech/sources/arxiv-artificial-intelligence.md>)

Topics: [Agentic AI](<https://devfeed.tech/topics/what-is-agentic-ai.md>), [AI for science](<https://devfeed.tech/topics/ai-for-science.md>), [Multi Agent Systems](<https://devfeed.tech/topics/multi-agent-systems.md>), [decision-making](<https://devfeed.tech/topics/decision-making.md>), [Artificial Intelligence](<https://devfeed.tech/topics/ai.md>), [knowledge-engineering](<https://devfeed.tech/topics/knowledge-engineering.md>)

Tags: [agents](<https://devfeed.tech/tags/agents.md>), [arxiv](<https://devfeed.tech/tags/arxiv.md>), [autonomous](<https://devfeed.tech/tags/autonomous.md>), [bench](<https://devfeed.tech/tags/bench.md>), [cs-ai](<https://devfeed.tech/tags/cs-ai.md>), [discovery](<https://devfeed.tech/tags/discovery.md>), [drug-discovery](<https://devfeed.tech/tags/drug-discovery.md>), [experiments](<https://devfeed.tech/tags/experiments.md>), [exploration](<https://devfeed.tech/tags/exploration.md>), [interaction](<https://devfeed.tech/tags/interaction.md>), [investigations](<https://devfeed.tech/tags/investigations.md>), [knowledge](<https://devfeed.tech/tags/knowledge.md>), [novel](<https://devfeed.tech/tags/novel.md>), [parallel](<https://devfeed.tech/tags/parallel.md>), [pharmaceutical](<https://devfeed.tech/tags/pharmaceutical.md>), [prototype](<https://devfeed.tech/tags/prototype.md>), [public](<https://devfeed.tech/tags/public.md>), [q-bio-qm](<https://devfeed.tech/tags/q-bio-qm.md>), [real-world](<https://devfeed.tech/tags/real-world.md>), [research](<https://devfeed.tech/tags/research.md>), [scaling](<https://devfeed.tech/tags/scaling.md>), [site](<https://devfeed.tech/tags/site.md>)

## AI overview

PharmAgents2 combines Paper2Skill, which extracts transferable decision knowledge from public sources alongside expert-developed skills, with Self-Scaling Discovery, which uses parallel agents to explore targets, hypotheses, and strategies while sharing research context. On PharmAgents-Bench v0.1 (121 questions across nine decision scenarios and three end-to-end tasks), it outperformed evaluated baselines in most decision categories and had the highest process scores on all three end-to-end tasks. In three studies, human-run experiments supported the system's findings: a new LpxH allosteric-site inhibitor scaffold showed inhibitory activity and binding; nominated JAK1 compounds showed activity after the system prioritized covalent inhibition; and a newly identified target for a known bioactive molecule was confirmed to bind. These results are reported as a prototype toward autonomous end-to-end drug discovery.

## Source excerpt

arXiv:2611.07653v1 Announce Type: new Abstract: Drug discovery requires continuous scientific decision-making across a vast research space. We introduce PharmAgents2, an autonomous system for end-to-end drug discovery that combines knowledge-enhanced decision-making with organized large-scale exploration. Paper2Skill extracts transferable scientific decision knowledge from public sources and, together with expert-developed skills, supports research decisions. Self-Scaling Discovery expands exploration through parallel agents inheriting research context and decision-making capabilities across targets, scientific hypotheses, and discovery strategies. We introduce PharmAgents-Bench v0.1, comprising 121 questions across nine decision scenarios and three end-to-end tasks assessed with expert-defined process rubrics. PharmAgents2 outperforms evaluated baselines in most decision categories and achieves the highest process scores on all three end-to-end tasks. In three real-world studies, autonomous investigations generated findings subsequently supported by human-executed experiments. For LpxH, PharmAgents2 hypothesized a previously unreported allosteric site and screened compounds against it, identifying a novel inhibitor scaffold with experimentally confirmed inhibitory activity and binding. For JAK1, it prioritized a covalent inhibition strategy and nominated compounds with experimentally demonstrated activity. Starting from a known bioactive molecule, Self-Scaling Discovery explored candidate targets across the proteome and identified a new binding target, with the interaction subsequently confirmed experimentally. PharmAgents2 represents a prototype of a virtual pharmaceutical company, marking a step toward autonomous end-to-end drug discovery.